Illuminating somatostatin analog action at neuroendocrine tumor receptors

Brazeau, 1973, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone, Science, 179, 77, 10.1126/science.179.4068.77 Guillemin, 2005, Hypothalamic hormones a.k.a. hypothalamic releasing factors, J. Endocrinol., 184, 11, 10.1677/joe.1.05883 Schonbrunn, 2013, Somatostatin receptors, 262 Viollet, 2008, Somatostatinergic systems in brain: networks and functions, Mol. Cell. Endocrinol., 286, 75, 10.1016/j.mce.2007.09.007 Stengel, 2013, Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes, Curr. Pharm. Des., 19, 98 Van Op den Bosch, 2009, The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review, Regul. Pept., 156, 1, 10.1016/j.regpep.2009.04.003 de Lecea, 2005, Cortistatin: a natural somatostatin analog, J. Endocrinol. Invest., 28, 10 Siehler, 2008, Pharmacological profile of somatostatin and cortistatin receptors, Mol. Cell. Endocrinol., 286, 26, 10.1016/j.mce.2007.12.007 Robas, 2003, MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion, J. Biol. Chem., 278, 44400, 10.1074/jbc.M302456200 Colao, 2011, Resistance to somatostatin analogs in acromegaly, Endocr. Rev., 32, 247, 10.1210/er.2010-0002 Feelders, 2009, Medical therapy of acromegaly: efficacy and safety of somatostatin analogues, Drugs, 69, 2207, 10.2165/11318510-000000000-00000 Wynick, 1989, Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995), Clin. Endocrinol. (Oxf.), 30, 385, 10.1111/j.1365-2265.1989.tb00436.x Schonbrunn, 1978, Characterization of functional receptors for somatostatin in rat pituitary cells in culture, J. Biol. Chem., 253, 6473, 10.1016/S0021-9258(19)46957-3 Srikant, 1981, Receptor binding of somatostatin-28 is tissue specific, Nature, 294, 259, 10.1038/294259a0 Reubi, 1981, High affinity binding sites for a somatostatin-28 analog in rat brain, Life Sci., 28, 2191, 10.1016/0024-3205(81)90628-7 Reubi, 1986, Distribution of somatostatin receptors in the human brain: an autoradiographic study, Neuroscience, 18, 329, 10.1016/0306-4522(86)90158-2 Hoyer, 1995, Classification and nomenclature of somatostatin receptors, Trends Pharmacol. Sci., 16, 86, 10.1016/S0165-6147(00)88988-9 Vanetti, 1992, Cloning and expression of a novel mouse somatostatin receptor (SSTR2B), FEBS Lett., 311, 290, 10.1016/0014-5793(92)81122-3 Cordoba-Chacon, 2011, Truncated somatostatin receptors as new players in somatostatin–cortistatin pathophysiology, Ann. N. Y. Acad. Sci., 1220, 6, 10.1111/j.1749-6632.2011.05985.x Duran-Prado, 2009, Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors, J. Clin. Endocrinol. Metab., 94, 2634, 10.1210/jc.2008-2564 Gadelha, 2013, Novel pathway for somatostatin analogs in patients with acromegaly, Trends Endocrinol. Metab., 24, 238, 10.1016/j.tem.2012.11.007 Korner, 2005, Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography, Am. J. Surg. Pathol., 29, 1642, 10.1097/01.pas.0000174013.14569.90 Park, 2012, Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release, Proc. Natl. Acad. Sci. U.S.A., 109, 19003, 10.1073/pnas.1209590109 Somvanshi, 2012, Pathophysiology of GPCR homo- and heterodimerization: special emphasis on somatostatin receptors, Pharmaceuticals, 5, 417, 10.3390/ph5050417 Reubi, 1984, High density of somatostatin receptors in pituitary tumors from acromegalic patients, J. Clin. Endocrinol. Metab., 59, 1148, 10.1210/jcem-59-6-1148 Reubi, 2003, Peptide receptors as molecular targets for cancer diagnosis and therapy, Endocr. Rev., 24, 389, 10.1210/er.2002-0007 Reubi, 1996, Local upregulation of neuropeptide receptors in host blood vessels around human colorectal cancers, Gastroenterology, 110, 1719, 10.1053/gast.1996.v110.pm8964396 Reubi, 1998, Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs, Blood, 92, 191, 10.1182/blood.V92.1.191.413k12_191_197 Reubi, 1999, Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts, J. Clin. Endocrinol. Metab., 84, 2942, 10.1210/jc.84.8.2942 Gugger, 2004, Cellular detection of sst2A receptors in human gastrointestinal tissue, Gut, 53, 1431, 10.1136/gut.2004.042002 Volante, 2007, Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy, Mod. Pathol., 20, 1172, 10.1038/modpathol.3800954 Fischer, 2008, Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1, J. Clin. Endocrinol. Metab., 93, 4519, 10.1210/jc.2008-1063 Korner, 2012, Somatostatin receptors subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting, Am. J. Surg. Pathol., 36, 242, 10.1097/PAS.0b013e31823d07f3 Reubi, 1998, Immunohistochemical localization of somatostatin receptors sst2A in human tumors, Am. J. Pathol., 153, 233, 10.1016/S0002-9440(10)65564-2 Lupp, 2011, Reassessment of sst5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4, Neuroendocrinology, 94, 255, 10.1159/000329876 Pyke, 2013, The glucagon-like peptide-1 receptor – or not?, Endocrinology, 154, 4, 10.1210/en.2012-2124 Michel, 2009, How reliable are G-protein-coupled receptor antibodies?, Naunyn Schmiedebergs Arch. Pharmacol., 379, 385, 10.1007/s00210-009-0395-y Reubi, 2001, Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands, Eur. J. Nucl. Med., 28, 836, 10.1007/s002590100541 Reubi, 2003, Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting, Eur. J. Nucl. Med., 30, 781, 10.1007/s00259-003-1184-3 Reubi, 1990, Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas, Cancer Res., 50, 5969 Reubi, 1989, The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status, J. Clin. Endocrinol. Metab., 68, 844, 10.1210/jcem-68-4-844 Corbetta, 2001, Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression, Eur. J. Clin. Invest., 31, 208, 10.1046/j.1365-2362.2001.00786.x Gatto, 2013, Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly, J. Clin. Endocrinol. Metab., 98, E66, 10.1210/jc.2012-2609 Nakashima, 2009, Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas, Endocr. J., 56, 295, 10.1507/endocrj.K08E-305 Fougner, 2008, The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma, Clin. Endocrinol. (Oxf.), 68, 458, 10.1111/j.1365-2265.2007.03065.x Acunzo, 2008, Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas, Cancer Res., 68, 10163, 10.1158/0008-5472.CAN-08-1857 Hofland, 2008, Somatostatin and somatostatin receptors in Cushing's disease, Mol. Cell. Endocrinol., 286, 199, 10.1016/j.mce.2007.10.015 Bertherat, 2003, Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study, J. Clin. Endocrinol. Metab., 88, 5353, 10.1210/jc.2002-021895 Colao, 2009, Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study, J. Clin. Endocrinol. Metab., 94, 3746, 10.1210/jc.2009-0941 Frohman, 1990, Somatostatin secretion and action in the regulation of growth hormone secretion, Metabolism, 39, 43, 10.1016/0026-0495(90)90208-T Kvols, 1993, Metastatic carcinoid tumors and the malignant carcinoid syndrome, Acta Oncol., 32, 197, 10.3109/02841869309083912 Maecke, 2011, Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment, J. Nucl. Med., 52, 841, 10.2967/jnumed.110.084236 Pyronnet, 2008, Antitumor effects of somatostatin, Mol. Cell. Endocrinol., 286, 230, 10.1016/j.mce.2008.02.002 Woltering, 2003, Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives, Cancer Biother. Radiopharm., 18, 601, 10.1089/108497803322287691 Sharma, 1998, Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells, Int. J. Cancer, 76, 259, 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7 Schally, 2001, Hypothalamic hormones and cancer, Front. Neuroendocrinol., 22, 248, 10.1006/frne.2001.0217 Koch, 1984, The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes, Endocrinology, 114, 1784, 10.1210/endo-114-5-1784 Gu, 1995, Development and use of a receptor antibody to characterize the interaction between somatostatin receptor sst1 and G proteins, Mol. Pharmacol., 48, 1004 Gu, 1997, Coupling specificity between somatostatin receptor sst2A and G proteins: isolation of the receptor-G protein complex with a receptor antibody, Mol. Endocrinol., 11, 527, 10.1210/me.11.5.527 Peverelli, 2013, Specific roles of Gi protein family members revealed by dissecting SST5 coupling in human pituitary cells, J. Cell Sci., 126, 638, 10.1242/jcs.116434 Schonbrunn, 1987, Mechanism by which somatostatin inhibits pituitary hormone release, 121 White, 1991, Somatostatin stimulates Ca2+-activated K+ channels through protein dephosphorylation, Nature, 351, 570, 10.1038/351570a0 Koch, 1988, Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin, J. Biol. Chem., 263, 216, 10.1016/S0021-9258(19)57381-1 Koch, 1985, Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP-independent actions of somatostatin. Evidence for coupling of Ni to decreases in intracellular free calcium, J. Biol. Chem., 260, 13138, 10.1016/S0021-9258(17)38849-X Koch, 1988, Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. II. An increase in potassium conductance initiates somatostatin-induced inhibition of prolactin secretion, J. Biol. Chem., 263, 226, 10.1016/S0021-9258(19)57382-3 Luini, 1990, Evidence that receptor-linked G protein inhibits exocytosis by a post-second-messenger mechanism in AtT-20 cells, J. Neurochem., 54, 30, 10.1111/j.1471-4159.1990.tb13279.x Ullrich, 1990, Somatostatin inhibition of Ca2+-induced insulin secretion in permeabilized HIT-T15 cells, Biochem. J., 270, 273, 10.1042/bj2700273 Betke, 2012, GPCR mediated regulation of synaptic transmission, Prog. Neurobiol., 96, 304, 10.1016/j.pneurobio.2012.01.009 Zhou, 2013, Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma, Mol. Cell. Endocrinol., 10.1016/j.mce.2013.09.006 Gadelha, 2013, Genetics of pituitary adenomas, Front. Horm. Res., 41, 111, 10.1159/000345673 Mantovani, 2010, GNAS imprinting and pituitary tumors, Mol. Cell. Endocrinol., 326, 15, 10.1016/j.mce.2010.04.009 Resmini, 2007, Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient, J. Clin. Endocrinol. Metab., 92, 1592, 10.1210/jc.2006-2084 Casarini, 2006, Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3, J. Endocrinol. Invest., 29, 826, 10.1007/BF03347378 Dent, 1997, S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ, Cell. Signal., 9, 539, 10.1016/S0898-6568(97)00048-X Reardon, 1997, Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness, Mol. Endocrinol., 11, 1062, 10.1210/me.11.8.1062 Florio, 2008, Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases, Mol. Cell. Endocrinol., 286, 40, 10.1016/j.mce.2007.08.012 Florio, 2008, Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors, Front. Biosci., 13, 822, 10.2741/2722 Tentler, 1997, Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency, Mol. Endocrinol., 11, 859, 10.1210/me.11.7.859 Drozdov, 2011, Gene network inference and biochemical assessment delineates GPCR pathways and CREB targets in small intestinal neuroendocrine neoplasia, PLoS ONE, 6, e22457, 10.1371/journal.pone.0022457 Emery, 2013, Rapgef2 connects GPCR-mediated cAMP signals to ERK activation in neuronal and endocrine cells, Sci. Signal., 6, ra51, 10.1126/scisignal.2003993 Kalhan, 2012, Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy, Purinergic Signal., 8, 265, 10.1007/s11302-011-9280-5 Germano, 2009, PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells, J. Mol. Neurosci., 39, 391, 10.1007/s12031-009-9283-7 Cuny, 2011, Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy, Ann. N. Y. Acad. Sci., 1220, 60, 10.1111/j.1749-6632.2010.05924.x Murthy, 1996, Somatostatin receptor-mediated signaling in smooth muscle. Activation of phospholipase C-β3 by Gβγ and inhibition of adenylyl cyclase by Gαi1 and Gαo, J. Biol. Chem., 271, 23458, 10.1074/jbc.271.38.23458 Taylor, 1995, Somatostatin (SSTR2) receptors mediate phospholipase C-independent Ca2+ mobilization in rat AR42J pancreas cells, Biochem. Biophys. Res. Commun., 214, 81, 10.1006/bbrc.1995.2259 Cescato, 2010, Agonist biased signaling at the sst2A receptor: the pan-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways, Mol. Endocrinol., 24, 240, 10.1210/me.2009-0321 Zatelli, 2005, SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma, Endocrinology, 146, 2692, 10.1210/en.2005-0001 Hubina, 2006, Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours, Eur. J. Endocrinol., 155, 371, 10.1530/eje.1.02213 Van-Ham, 2007, Differential signaling of dopamine-D2S and -D2L receptors to inhibit ERK1/2 phosphorylation, J. Neurochem., 102, 1796, 10.1111/j.1471-4159.2007.04650.x Kidd, 2008, Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines, Cancer, 113, 690, 10.1002/cncr.23700 Cervia, 2007, An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology, Pharmacol. Ther., 116, 322, 10.1016/j.pharmthera.2007.06.010 Ben-Shlomo, 2010, Pituitary somatostatin receptor signaling, Trends Endocrinol. Metab., 21, 123, 10.1016/j.tem.2009.12.003 Cakir, 2010, Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways, J. Cell. Mol. Med., 14, 2570, 10.1111/j.1582-4934.2010.01125.x Hukovic, 1996, Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation, Endocrinology, 137, 4046, 10.1210/en.137.9.4046 Tulipano, 2004, Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes, J. Biol. Chem., 279, 21374, 10.1074/jbc.M313522200 Schonbrunn, 2008, Selective agonism in somatostatin receptor signaling and regulation, Mol. Cell. Endocrinol., 286, 35, 10.1016/j.mce.2007.09.009 Csaba, 2012, Molecular mechanisms of somatostatin receptor trafficking, J. Mol. Endocrinol., 48, R1, 10.1530/JME-11-0121 Hipkin, 1997, Agonist-induced desensitization, internalization and phosphorylation of the sst2A somatostatin receptor, J. Biol. Chem., 272, 13869, 10.1074/jbc.272.21.13869 Elberg, 2002, Homologous and heterologous regulation of somatostatin receptor 2, Mol. Endocrinol., 16, 2502, 10.1210/me.2002-0207 Waser, 2009, Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues, J. Nucl. Med., 50, 936, 10.2967/jnumed.108.061457 Reubi, 2010, Internalized Sst2 receptors in neuroendocrine tumors of octreotide-treated patients, J. Clin. Endocrinol. Metab., 95, 2343, 10.1210/jc.2009-2487 Hipkin, 2000, Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor, J. Biol. Chem., 275, 5591, 10.1074/jbc.275.8.5591 Liu, 2009, Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation, Mol. Pharmacol., 76, 68, 10.1124/mol.108.054262 Poll, 2010, Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation, Mol. Endocrinol., 24, 436, 10.1210/me.2009-0315 Ghosh, 2011, Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation, J. Biol. Chem., 286, 13561, 10.1074/jbc.M110.215723 Liu, 2008, Distinct phosphorylation sites in the SST2A somatostatin receptor control internalization, desensitization, and arrestin binding, Mol. Pharmacol., 73, 292, 10.1124/mol.107.038570 Gurevich, 2008, Arrestins as multi-functional signaling adaptors, Handb. Exp. Pharmacol., 186, 15, 10.1007/978-3-540-72843-6_2 Kao, 2011, Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists, Mol. Endocrinol., 25, 1040, 10.1210/me.2010-0398 Poll, 2011, Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling, J. Biol. Chem., 286, 32931, 10.1074/jbc.M111.224899 Liu, 2003, In vivo phosphorylation of the somatostatin 2A receptor in human tumors, J. Clin. Endocrinol. Metab., 88, 6073, 10.1210/jc.2003-030986 Waser, 2012, Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients, Am. J. Pathol., 180, 1942, 10.1016/j.ajpath.2012.01.041 Peverelli, 2008, The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation, Mol. Endocrinol., 22, 676, 10.1210/me.2007-0068 Petrich, 2013, Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor, Mol. Endocrinol., 27, 671, 10.1210/me.2012-1329 Roth, 1997, Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization, J. Biol. Chem., 272, 23769, 10.1074/jbc.272.38.23769 Nouel, 1997, Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives, Endocrinology, 138, 296, 10.1210/en.138.1.296 Liu, 2001, Agonist-induced phosphorylation of somatostatin receptor subtype 1 (sst1). Relationship to desensitization and internalization, J. Biol. Chem., 276, 3709, 10.1074/jbc.M008873200 Roosterman, 2007, Agonist-induced endocytosis of rat somatostatin receptor 1, Endocrinology, 148, 1050, 10.1210/en.2006-1600 Smalley, 1998, Differential agonist activity of somatostatin and L-362855 at human recombinant sst4 receptors, Br. J. Pharmacol., 125, 833, 10.1038/sj.bjp.0702133 Kreienkamp, 1998, Rat somatostatin receptor subtype 4 can be made sensitive to agonist-induced internalization by mutation of a single threonine (residue 331), DNA Cell Biol., 17, 869, 10.1089/dna.1998.17.869 Butcher, 2012, Physiological role of G-protein coupled receptor phosphorylation, Handb. Exp. Pharmacol., 208, 79, 10.1007/978-3-642-23274-9_5 Butcher, 2011, Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code, J. Biol. Chem., 286, 11506, 10.1074/jbc.M110.154526 Weckbecker, 2003, Opportunities in somatostatin research: biological, chemical and therapeutic aspects, Nat. Rev. Drug Discov., 2, 999, 10.1038/nrd1255 Bauer, 1982, SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action, Life Sci., 31, 1133, 10.1016/0024-3205(82)90087-X Pless, 1986, Chemistry and pharmacology of SMS 201–995, a long-acting octapeptide analogue of somatostatin, Scand. J. Gastroenterol., 21, 54, 10.3109/00365528609087432 Reubi, 1984, Evidence for two somatostatin-14 receptor types in rat brain cortex, Neurosci. Lett., 49, 259, 10.1016/0304-3940(84)90299-4 Reubi, 1985, New specific radioligand for one subpopulation of brain somatostatin receptors, Life Sci., 36, 1829, 10.1016/0024-3205(85)90155-9 Maurer, 1985, Brain somatostatin receptor subpopulation visualized by autoradiography, Brain Res., 333, 178, 10.1016/0006-8993(85)90142-8 Oberg, 2010, Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy, Gastroenterology, 139, 742, 10.1053/j.gastro.2010.07.002 Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group, J. Clin. Oncol., 27, 4656, 10.1200/JCO.2009.22.8510 Bevan, 2005, Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly, J. Clin. Endocrinol. Metab., 90, 1856, 10.1210/jc.2004-1093 Strosberg, 2010, Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors, World J. Gastroenterol., 16, 2963, 10.3748/wjg.v16.i24.2963 Hejna, 2002, The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?, Ann. Oncol., 13, 653, 10.1093/annonc/mdf142 Reubi, 2002, A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors, Eur. J. Pharmacol., 456, 45, 10.1016/S0014-2999(02)02651-1 Kvols, 2012, Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study, Endocr. Relat. Cancer, 19, 657, 10.1530/ERC-11-0367 Colao, 2012, A 12-month phase 3 study of pasireotide in Cushing's disease, N. Engl. J. Med., 366, 914, 10.1056/NEJMoa1105743 Afargan, 2001, Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin, Endocrinology, 142, 477, 10.1210/en.142.1.477 Plockinger, 2012, DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours, Eur. J. Endocrinol., 166, 223, 10.1530/EJE-11-0737 Culler, 2011, Somatostatin–dopamine chimeras: a novel approach to treatment of neuroendocrine tumors, Horm. Metab. Res., 43, 854, 10.1055/s-0031-1287769 ClinicalTrials.gov (2010) Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly (TULIPIA) (http://clinicaltrials.gov/show/NCT00994214) Ipsen (2010) Ipsen Closes its BIM 23A760 Trials, 15 December (http://www.ipsen.com/wp-content/uploads/2013/03/PR-Ipsen-BIM-23A760-EN-FINAL.pdf) Kenakin, 2010, Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery, Pharmacol. Rev., 62, 265, 10.1124/pr.108.000992 Liu, 2005, Receptor signaling and endocytosis are differentially regulated by somatostatin analogs, Mol. Pharmacol., 68, 90, 10.1124/mol.105.011767 Lesche, 2009, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro, J. Clin. Endocrinol. Metab., 94, 654, 10.1210/jc.2008-1919 Feelders, 2013, Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors, Drugs Today (Barc.), 49, 89, 10.1358/dot.2013.49.2.1915142 Henry, 2013, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers, J. Clin. Endocrinol. Metab., 98, 3446, 10.1210/jc.2013-1771 Reubi, 1998, Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets, J. Clin. Endocrinol. Metab., 83, 3746, 10.1210/jc.83.10.3746 Kailey, 2012, SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells, Am. J. Physiol. Endocrinol. Metab., 303, E1107, 10.1152/ajpendo.00207.2012 Kwekkeboom, 2008, Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival, J. Clin. Oncol., 26, 2124, 10.1200/JCO.2007.15.2553 Reubi, 2008, Peptide-based probes for cancer imaging, J. Nucl. Med., 49, 1735, 10.2967/jnumed.108.053041 Wild, 2005, 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5, Eur. J. Nucl. Med. Mol. Imaging, 32, 724, 10.1007/s00259-004-1697-4 Wild, 2003, DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals, Eur. J. Nucl. Med. Mol. Imaging, 30, 1338, 10.1007/s00259-003-1255-5 Wild, 2013, Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors, J. Nucl. Med., 54, 364, 10.2967/jnumed.112.111724 Ginj, 2008, New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting, Clin. Cancer Res., 14, 2019, 10.1158/1078-0432.CCR-07-1687 Eberlein, 2012, Biodistribution and dosimetry of [68Ga]-DOTASOM targeting somatostatin receptors in a pig model, Eur. J. Nucl. Med. Mol. Imaging, 39, S325 Tatsi, 2010, First evidence of in vivo targeting of hsst2A/3/5+-tumors with the pansomatostatin-like radioligand [111In-DOTA0]LTT-SS28, Eur. J. Nucl. Med., 37, S299 Tatsi, 2012, [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers – first results of a preclinical study, EJNMMI Res., 2, 25, 10.1186/2191-219X-2-25 Cescato, 2006, Internalization of sst2, sst3 and sst5 receptors: effects of somatostatin agonists and antagonists, J. Nucl. Med., 47, 502 Ginj, 2006, Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors, Proc. Natl. Acad. Sci. U.S.A., 103, 16436, 10.1073/pnas.0607761103 Wild, 2010, First clinical evaluation of somatostatin receptor antagonist imaging, J. Nucl. Med., 51, 483 Cescato, 2008, Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting, J. Med. Chem., 51, 4030, 10.1021/jm701618q